Oliver Luxxe Assets’s Thermo Fisher Scientific TMO Stock Holding History

Oliver Luxxe Assets’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.17M	Buy	10,319 +248	+2%	+$119K	0.76%	48
2026 Q1	$4.95M	Buy	+10,071	New	+$5.47M	0.74%	51
2025 Q2	–	Sell	-9,767	Closed	-$4.86M	–	204
2025 Q1	$4.86M	Sell	9,767 -8,600	-47%	-$4.66M	0.9%	40
2024 Q4	$10.4M	Buy	18,367 +9,461	+106%	+$5.2M	0.92%	36
2024 Q3	$5.51M	Sell	8,906 -52	-0.6%	-$30.8K	0.98%	32
2024 Q2	$4.95M	Hold	8,958	–	–	1.05%	31
2024 Q1	$5.21M	Buy	8,958 +44	+0.5%	+$24.7K	1.09%	29
2023 Q4	$4.73M	Buy	8,914 +108	+1%	+$52.3K	1.11%	27
2023 Q3	$4.46M	Buy	8,806 +140	+2%	+$74.6K	1.14%	29
2023 Q2	$4.52M	Sell	8,666 -76	-0.9%	-$41K	1.13%	29
2023 Q1	$5.04M	Buy	8,742 +59	+0.7%	+$33.3K	1.33%	18
2022 Q4	$4.78M	Buy	8,683 +257	+3%	+$136K	1.33%	18
2022 Q3	$4.27M	Buy	8,426 +160	+2%	+$89.5K	1.34%	15
2022 Q2	$4.49M	Buy	8,266 +90	+1%	+$49.5K	1.33%	20
2022 Q1	$4.83M	Buy	8,176 +231	+3%	+$133K	1.22%	19
2021 Q4	$5.3M	Buy	7,945 +1,970	+33%	+$1.23M	1.34%	13
2021 Q3	$3.41M	Buy	5,975 +15	+0.3%	+$8.23K	0.94%	31
2021 Q2	$3.01M	Buy	5,960 +94	+2%	+$44.4K	0.82%	40
2021 Q1	$2.68M	Sell	5,866 -2,621	-31%	-$1.25M	0.8%	43
2020 Q4	$4.36M	Sell	8,487 -295	-3%	-$138K	1.36%	10
2020 Q3	$3.88M	Sell	8,782 -532	-6%	-$220K	1.44%	13
2020 Q2	$3.38M	Sell	9,314 -337	-3%	-$113K	1.78%	14
2020 Q1	$2.96M	Buy	9,651 +380	+4%	+$120K	1.86%	12
2019 Q4	$3.01M	Buy	9,271 +28	+0.3%	+$8.49K	1.57%	21
2019 Q3	$2.62M	Sell	9,243 -153	-2%	-$43.8K	1.52%	24
2019 Q2	$2.8M	Sell	9,396 -335	-3%	-$92.3K	1.55%	22
2019 Q1	$2.66M	Sell	9,731 -374	-4%	-$93.1K	1.54%	24
2018 Q4	$2.26M	Buy	10,105 +108	+1%	+$25.3K	1.52%	31
2018 Q3	$2.41M	Sell	9,997 -7,169	-42%	-$1.65M	1.37%	34
2018 Q2	$3.54M	Hold	17,166	–	–	2.25%	11
2018 Q1	$3.54M	Sell	17,166 -398	-2%	-$83.5K	2.19%	11
2017 Q4	$3.33M	Buy	+17,564	New	+$3.36M	2.02%	20
2016 Q1	–	Sell	-1,614	Closed	-$211K	–	98
2015 Q4	$211K	Buy	+1,614	New	+$215K	0.19%	96

Other funds holding TMO

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Lindsell Train London, United Kingdom $2.63B AUM 2.97% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Canoe Financial Calgary, Alberta, Canada $8.07B AUM 25.47% 1-Year Est. Return

Sarasin & Partners London, United Kingdom $8.54B AUM 9.6% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

Oliver Luxxe Assets's TMO Position: Q2 2026 in Review

Oliver Luxxe Assets increased its Thermo Fisher Scientific (TMO) stake by 2.5% in Q2 2026, buying an estimated $119K and bringing the position to 10,319 shares worth $5.17M. The position accounts for 0.76% of the portfolio, ranked #48.

Oliver Luxxe Assets first reported a position in TMO in Q4 2015 and has held it in 33 quarters since. The position peaked at $10.4M in Q4 2024. 429 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

Oliver Luxxe Assets held 10,319 shares of Thermo Fisher Scientific worth $5.17M as of Q2 2026.
Oliver Luxxe Assets bought 248 Thermo Fisher Scientific shares in Q2 2026, an estimated $119K.
Thermo Fisher Scientific made up 0.76% of Oliver Luxxe Assets's portfolio in Q2 2026, its #48 holding.
Oliver Luxxe Assets first reported a position in Thermo Fisher Scientific in Q4 2015 and has held it in 33 quarters since.
Oliver Luxxe Assets's Thermo Fisher Scientific position peaked at $10.4M in Q4 2024.
429 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Oliver Luxxe Assets's 13F filing for Q2 2026, filed 9 Jul 2026.